Psoriasis Drugs Market by Product Type, End-Users, and Geography (North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa): Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025 - 2032
Description
Persistence Market Research has recently published a detailed report on the global Psoriasis Drugs Market, offering a comprehensive overview of the market's key dynamics such as growth drivers, emerging trends, challenges, and potential opportunities. The report provides valuable insights into the evolving treatment landscape, equipping stakeholders with the information necessary to make informed strategic decisions.
Key Insights:
The global psoriasis drugs market includes a variety of medications aimed at treating psoriasis, a chronic inflammatory skin condition. These drugs, ranging from topical formulations to systemic biologics, help reduce inflammation, slow skin cell growth, and alleviate symptoms. Increased focus on innovative biologic therapies, a growing patient population, and enhanced healthcare infrastructure are transforming treatment approaches. Continuous advancements in pharmaceutical R&D are also paving the way for new and more effective drug formulations.
Market Growth Drivers:
The growth of the psoriasis drugs market is driven by several critical factors, including the rising global prevalence of psoriasis and the growing demand for advanced treatment options. Increased awareness about the disease and greater access to dermatological care are encouraging more patients to seek medical intervention. The introduction of biologics and targeted therapies has significantly improved treatment outcomes, spurring market expansion. Additionally, favorable healthcare policies, rising healthcare expenditures, and a strong pipeline of novel drugs are contributing to sustained market growth.
Market Restraints:
Despite positive growth prospects, the psoriasis drugs market is not without its challenges. High treatment costs, particularly for biologics, remain a barrier in low-income and developing regions. Long-term safety concerns and adverse side effects associated with some therapies can affect patient adherence and regulatory approvals. Additionally, the limited availability of advanced drugs in rural areas and a lack of awareness in certain populations may hinder the market’s full potential. Patent expiries and generic competition also pose threats to leading market players.
Market Opportunities:
The psoriasis drugs market presents substantial opportunities for growth, particularly with the rise of biosimilars and personalized medicine. Ongoing innovation in immunology and drug delivery systems is expected to yield more effective and accessible treatments. Expansion into emerging markets, where awareness and access are improving, offers promising growth potential. Collaborations between biotech firms and large pharmaceutical companies are accelerating research and expanding distribution networks. Moreover, digital healthcare platforms and telemedicine are opening new channels for diagnosis and treatment delivery in remote regions.
Key Questions Answered in the Report:
Key players in the psoriasis drugs market, including Janssen Biotech, Novartis, Amgen, and Pfizer, are focusing on developing advanced biologics and expanding global market reach. These companies are investing heavily in R&D to bring new treatments to market, improve patient outcomes, and reduce side effects. Strategic partnerships, mergers, and product launches are common tactics to stay competitive. As demand for effective and affordable treatments grows, companies are also targeting biosimilar development and exploring opportunities in emerging economies to strengthen their market positions.
Companies Covered in This Report:
By Drug Class:
Please Note: It will take 5 business days to complete the report upon order confirmation.
Key Insights:
- Psoriasis Drugs Market Size (2025E): US$ 20.9 Bn
- Projected Market Value (2032F): US$ 33.4 Bn
- Global Market Growth Rate (CAGR 2025 to 2032): 6.9%
The global psoriasis drugs market includes a variety of medications aimed at treating psoriasis, a chronic inflammatory skin condition. These drugs, ranging from topical formulations to systemic biologics, help reduce inflammation, slow skin cell growth, and alleviate symptoms. Increased focus on innovative biologic therapies, a growing patient population, and enhanced healthcare infrastructure are transforming treatment approaches. Continuous advancements in pharmaceutical R&D are also paving the way for new and more effective drug formulations.
Market Growth Drivers:
The growth of the psoriasis drugs market is driven by several critical factors, including the rising global prevalence of psoriasis and the growing demand for advanced treatment options. Increased awareness about the disease and greater access to dermatological care are encouraging more patients to seek medical intervention. The introduction of biologics and targeted therapies has significantly improved treatment outcomes, spurring market expansion. Additionally, favorable healthcare policies, rising healthcare expenditures, and a strong pipeline of novel drugs are contributing to sustained market growth.
Market Restraints:
Despite positive growth prospects, the psoriasis drugs market is not without its challenges. High treatment costs, particularly for biologics, remain a barrier in low-income and developing regions. Long-term safety concerns and adverse side effects associated with some therapies can affect patient adherence and regulatory approvals. Additionally, the limited availability of advanced drugs in rural areas and a lack of awareness in certain populations may hinder the market’s full potential. Patent expiries and generic competition also pose threats to leading market players.
Market Opportunities:
The psoriasis drugs market presents substantial opportunities for growth, particularly with the rise of biosimilars and personalized medicine. Ongoing innovation in immunology and drug delivery systems is expected to yield more effective and accessible treatments. Expansion into emerging markets, where awareness and access are improving, offers promising growth potential. Collaborations between biotech firms and large pharmaceutical companies are accelerating research and expanding distribution networks. Moreover, digital healthcare platforms and telemedicine are opening new channels for diagnosis and treatment delivery in remote regions.
Key Questions Answered in the Report:
- What are the primary factors fueling the growth of the global psoriasis drugs market?
- Which drug types and delivery methods are driving demand?
- How is innovation in biologics and immunotherapies shaping market trends?
- Who are the leading players and what strategies are they adopting?
- What are the key regional trends and future projections for this market?
Key players in the psoriasis drugs market, including Janssen Biotech, Novartis, Amgen, and Pfizer, are focusing on developing advanced biologics and expanding global market reach. These companies are investing heavily in R&D to bring new treatments to market, improve patient outcomes, and reduce side effects. Strategic partnerships, mergers, and product launches are common tactics to stay competitive. As demand for effective and affordable treatments grows, companies are also targeting biosimilar development and exploring opportunities in emerging economies to strengthen their market positions.
Companies Covered in This Report:
- Janssen Biotech, Inc.
- Novartis International Ltd.
- Amgen Inc.
- Pfizer Inc.
- Takeda Pharmaceutical Company Ltd.
- Merck & Co, Inc.
- AbbVie Inc.
- Eli Lilly and Company
- Boehringer Ingelheim GmbH
- Sun Pharmaceutical Industries Ltd.
- Johnson & Johnson
- LEO Pharma
- UCB
- AstraZeneca
- Celgene Corporation
By Drug Class:
- Interleukin Inhibitors
- Corticosteroids
- Anti-inflammatory
- Glucocorticoids
- TNF alfa Inhibitor
- Others
- Topical
- Oral
- Injectable
- Others
- Guttate Psoriasis
- Inverse Psoriasis
- Pustular Psoriasis
- Erythrodermic Psoriasis
- Plaque Psoriasis
- Others
- Hospital Pharmacies
- Retail Pharmacies
- e-Commerce
- North America
- Europe
- East Asia
- South Asia and Oceania
- Latin America
- Middle East and Africa
Please Note: It will take 5 business days to complete the report upon order confirmation.
Table of Contents
195 Pages
- 1. Executive Summary
- 1.1. Global Psoriasis Drugs Market Snapshot, 2025 and 2032
- 1.2. Market Opportunity Assessment, 2025-2032, US$ Mn
- 1.3. Key Market Trends
- 1.4. Future Market Projections
- 1.5. Premium Market Insights
- 1.6. Industry Developments and Key Market Events
- 1.7. PMR Analysis and Recommendations
- 2. Market Overview
- 2.1. Market Scope and Definition
- 2.2. Market Dynamics
- 2.2.1. Drivers
- 2.2.2. Restraints
- 2.2.3. Opportunity
- 2.2.4. Key Trends
- 2.3. Macro-Economic Factors
- 2.3.1. Global Sectorial Outlook
- 2.3.2. Global GDP Growth Outlook
- 2.4. COVID-19 Impact Analysis
- 2.5. Forecast Factors - Relevance and Impact
- 3. Value Added Insights
- 3.1. Drug Class Adoption Analysis
- 3.2. Regulatory Landscape
- 3.3. Pipeline Assessment
- 3.4. Disease Epidemiology
- 3.5. Key Deals and Mergers
- 3.6. PESTLE Analysis
- 3.7. Value Chain Analysis
- 3.8. Porter’s Five Force Analysis
- 4. Global Psoriasis Drugs Market Outlook:
- 4.1. Key Highlights
- 4.1.1. Market Size (US$ Mn) and Y-o-Y Growth
- 4.1.2. Absolute $ Opportunity
- 4.2. Market Size (US$ Mn) Analysis and Forecast
- 4.2.1. Historical Market Size (US$ Mn) Analysis, 2019-2024
- 4.2.2. Market Size (US$ Mn) Analysis and Forecast, 2025-2032
- 4.3. Global Psoriasis Drugs Market Outlook: Drug Class
- 4.3.1. Introduction / Key Findings
- 4.3.2. Historical Market Size (US$ Mn) Analysis, By Drug Class, 2019-2024
- 4.3.3. Market Size (US$ Mn) Analysis and Forecast, By Drug Class, 2025-2032
- 4.3.3.1. Interleukin Inhibitors
- 4.3.3.2. Corticosteroids
- 4.3.3.3. Anti-inflammatory
- 4.3.3.4. Glucocorticoids
- 4.3.3.5. Tnf alfa Inhibitor
- 4.3.3.6. Others
- 4.3.4. Market Attractiveness Analysis: Drug Class
- 4.4. Global Psoriasis Drugs Market Outlook: Mode of Administration
- 4.4.1. Introduction / Key Findings
- 4.4.2. Historical Market Size (US$ Mn) Analysis, By Mode of Administration, 2019-2024
- 4.4.3. Market Size (US$ Mn) Analysis and Forecast, By Mode of Administration, 2025-2032
- 4.4.3.1. Topical
- 4.4.3.2. Oral
- 4.4.3.3. Injectable
- 4.4.3.4. Others
- 4.4.4. Market Attractiveness Analysis: Mode of Administration
- 4.5. Global Psoriasis Drugs Market Outlook: Indication
- 4.5.1. Introduction / Key Findings
- 4.5.2. Historical Market Size (US$ Mn) Analysis, By Indication, 2019-2024
- 4.5.3. Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025-2032
- 4.5.3.1. Guttate Psoriasis
- 4.5.3.2. Inverse Psoriasis
- 4.5.3.3. Pustular Psoriasis
- 4.5.3.4. Erythrodermic Psoriasis
- 4.5.3.5. Plaque Psoriasis
- 4.5.3.6. Others
- 4.5.4. Market Attractiveness Analysis: Indication
- 4.6. Global Psoriasis Drugs Market Outlook: Distribution Channel
- 4.6.1. Introduction / Key Findings
- 4.6.2. Historical Market Size (US$ Mn) Analysis, By Distribution Channel, 2019-2024
- 4.6.3. Market Size (US$ Mn) Analysis and Forecast, By Distribution Channel, 2025-2032
- 4.6.3.1. Hospital Pharmacies
- 4.6.3.2. Retail Pharmacies
- 4.6.3.3. e-Commerce
- 4.6.4. Market Attractiveness Analysis: Distribution Channel
- 5. Global Psoriasis Drugs Market Outlook: Region
- 5.1. Key Highlights
- 5.2. Historical Market Size (US$ Mn) Analysis, By Region, 2019-2024
- 5.3. Market Size (US$ Mn) Analysis and Forecast, By Region, 2025-2032
- 5.3.1. North America
- 5.3.2. Europe
- 5.3.3. East Asia
- 5.3.4. South Asia and Oceania
- 5.3.5. Latin America
- 5.3.6. Middle East & Africa
- 5.4. Market Attractiveness Analysis: Region
- 6. North America Psoriasis Drugs Market Outlook
- 6.1. Key Highlights
- 6.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
- 6.2.1. By Country
- 6.2.2. By Drug Class
- 6.2.3. By Mode of Administration
- 6.2.4. By Indication
- 6.2.5. By Distribution Channel
- 6.3. Market Size (US$ Mn) Analysis and Forecast By Country, 2025-2032
- 6.3.1. U.S.
- 6.3.2. Canada
- 6.4. Market Size (US$ Mn) Analysis and Forecast, By Drug Class, 2025-2032
- 6.4.1. Interleukin Inhibitors
- 6.4.2. Corticosteroids
- 6.4.3. Anti-inflammatory
- 6.4.4. Glucocorticoids
- 6.4.5. Tnf alfa Inhibitor
- 6.4.6. Others
- 6.5. Market Size (US$ Mn) Analysis and Forecast, By Mode of Administration, 2025-2032
- 6.5.1. Topical
- 6.5.2. Oral
- 6.5.3. Injectable
- 6.5.4. Others
- 6.6. Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025-2032
- 6.6.1. Guttate Psoriasis
- 6.6.2. Inverse Psoriasis
- 6.6.3. Pustular Psoriasis
- 6.6.4. Erythrodermic Psoriasis
- 6.6.5. Plaque Psoriasis
- 6.6.6. Others
- 6.7. Market Size (US$ Mn) Analysis and Forecast, By Distribution Channel, 2025-2032
- 6.7.1. Hospital Pharmacies
- 6.7.2. Retail Pharmacies
- 6.7.3. e-Commerce
- 6.8. Market Attractiveness Analysis
- 7. Europe Psoriasis Drugs Market Outlook
- 7.1. Key Highlights
- 7.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
- 7.2.1. By Country
- 7.2.2. By Drug Class
- 7.2.3. By Mode of Administration
- 7.2.4. By Indication
- 7.2.5. By Distribution Channel
- 7.3. Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
- 7.3.1. Germany
- 7.3.2. France
- 7.3.3. U.K.
- 7.3.4. Italy
- 7.3.5. Spain
- 7.3.6. Russia
- 7.3.7. Turkey
- 7.3.8. Rest of Europe
- 7.4. Market Size (US$ Mn) Analysis and Forecast, By Drug Class, 2025-2032
- 7.4.1. Interleukin Inhibitors
- 7.4.2. Corticosteroids
- 7.4.3. Anti-inflammatory
- 7.4.4. Glucocorticoids
- 7.4.5. Tnf alfa Inhibitor
- 7.4.6. Others
- 7.5. Market Size (US$ Mn) Analysis and Forecast, By Mode of Administration, 2025-2032
- 7.5.1. Topical
- 7.5.2. Oral
- 7.5.3. Injectable
- 7.5.4. Others
- 7.6. Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025-2032
- 7.6.1. Guttate Psoriasis
- 7.6.2. Inverse Psoriasis
- 7.6.3. Pustular Psoriasis
- 7.6.4. Erythrodermic Psoriasis
- 7.6.5. Plaque Psoriasis
- 7.6.6. Others
- 7.7. Market Size (US$ Mn) Analysis and Forecast, By Distribution Channel, 2025-2032
- 7.7.1. Hospital Pharmacies
- 7.7.2. Retail Pharmacies
- 7.7.3. e-Commerce
- 7.8. Market Attractiveness Analysis
- 8. East Asia Psoriasis Drugs Market Outlook
- 8.1. Key Highlights
- 8.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
- 8.2.1. By Country
- 8.2.2. By Drug Class
- 8.2.3. By Mode of Administration
- 8.2.4. By Indication
- 8.2.5. By Distribution Channel
- 8.3. Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
- 8.3.1. China
- 8.3.2. Japan
- 8.3.3. South Korea
- 8.4. Market Size (US$ Mn) Analysis and Forecast, By Drug Class, 2025-2032
- 8.4.1. Interleukin Inhibitors
- 8.4.2. Corticosteroids
- 8.4.3. Anti-inflammatory
- 8.4.4. Glucocorticoids
- 8.4.5. Tnf alfa Inhibitor
- 8.4.6. Others
- 8.5. Market Size (US$ Mn) Analysis and Forecast, By Mode of Administration, 2025-2032
- 8.5.1. Topical
- 8.5.2. Oral
- 8.5.3. Injectable
- 8.5.4. Others
- 8.6. Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025-2032
- 8.6.1. Guttate Psoriasis
- 8.6.2. Inverse Psoriasis
- 8.6.3. Pustular Psoriasis
- 8.6.4. Erythrodermic Psoriasis
- 8.6.5. Plaque Psoriasis
- 8.6.6. Others
- 8.7. Market Size (US$ Mn) Analysis and Forecast, By Distribution Channel, 2025-2032
- 8.7.1. Hospital Pharmacies
- 8.7.2. Retail Pharmacies
- 8.7.3. e-Commerce
- 8.8. Market Attractiveness Analysis
- 9. South Asia & Oceania Psoriasis Drugs Market Outlook
- 9.1. Key Highlights
- 9.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
- 9.2.1. By Country
- 9.2.2. By Drug Class
- 9.2.3. By Mode of Administration
- 9.2.4. By Indication
- 9.2.5. By Distribution Channel
- 9.3. Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
- 9.3.1. India
- 9.3.2. Southeast Asia
- 9.3.3. ANZ
- 9.3.4. Rest of South Asia & Oceania
- 9.4. Market Size (US$ Mn) Analysis and Forecast, By Drug Class, 2025-2032
- 9.4.1. Interleukin Inhibitors
- 9.4.2. Corticosteroids
- 9.4.3. Anti-inflammatory
- 9.4.4. Glucocorticoids
- 9.4.5. Tnf alfa Inhibitor
- 9.4.6. Others
- 9.5. Market Size (US$ Mn) Analysis and Forecast, By Mode of Administration, 2025-2032
- 9.5.1. Topical
- 9.5.2. Oral
- 9.5.3. Injectable
- 9.5.4. Others
- 9.6. Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025-2032
- 9.6.1. Guttate Psoriasis
- 9.6.2. Inverse Psoriasis
- 9.6.3. Pustular Psoriasis
- 9.6.4. Erythrodermic Psoriasis
- 9.6.5. Plaque Psoriasis
- 9.6.6. Others
- 9.7. Market Size (US$ Mn) Analysis and Forecast, By Distribution Channel, 2025-2032
- 9.7.1. Hospital Pharmacies
- 9.7.2. Retail Pharmacies
- 9.7.3. e-Commerce
- 9.8. Market Attractiveness Analysis
- 10. Latin America Psoriasis Drugs Market Outlook
- 10.1. Key Highlights
- 10.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
- 10.2.1. By Country
- 10.2.2. By Drug Class
- 10.2.3. By Mode of Administration
- 10.2.4. By Indication
- 10.2.5. By Distribution Channel
- 10.3. Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
- 10.3.1. Brazil
- 10.3.2. Mexico
- 10.3.3. Rest of Latin America
- 10.4. Market Size (US$ Mn) Analysis and Forecast, By Drug Class, 2025-2032
- 10.4.1. Interleukin Inhibitors
- 10.4.2. Corticosteroids
- 10.4.3. Anti-inflammatory
- 10.4.4. Glucocorticoids
- 10.4.5. Tnf alfa Inhibitor
- 10.4.6. Others
- 10.5. Market Size (US$ Mn) Analysis and Forecast, By Mode of Administration, 2025-2032
- 10.5.1. Topical
- 10.5.2. Oral
- 10.5.3. Injectable
- 10.5.4. Others
- 10.6. Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025-2032
- 10.6.1. Guttate Psoriasis
- 10.6.2. Inverse Psoriasis
- 10.6.3. Pustular Psoriasis
- 10.6.4. Erythrodermic Psoriasis
- 10.6.5. Plaque Psoriasis
- 10.6.6. Others
- 10.7. Market Size (US$ Mn) Analysis and Forecast, By Distribution Channel, 2025-2032
- 10.7.1. Hospital Pharmacies
- 10.7.2. Retail Pharmacies
- 10.7.3. e-Commerce
- 10.8. Market Attractiveness Analysis
- 11. Middle East & Africa Psoriasis Drugs Market Outlook
- 11.1. Key Highlights
- 11.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
- 11.2.1. By Country
- 11.2.2. By Drug Class
- 11.2.3. By Mode of Administration
- 11.2.4. By Indication
- 11.2.5. By Distribution Channel
- 11.3. Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
- 11.3.1. GCC Countries
- 11.3.2. Egypt
- 11.3.3. South Africa
- 11.3.4. Northern Africa
- 11.3.5. Rest of Middle East & Africa
- 11.4. Market Size (US$ Mn) Analysis and Forecast, By Drug Class, 2025-2032
- 11.4.1. Interleukin Inhibitors
- 11.4.2. Corticosteroids
- 11.4.3. Anti-inflammatory
- 11.4.4. Glucocorticoids
- 11.4.5. Tnf alfa Inhibitor
- 11.4.6. Others
- 11.5. Market Size (US$ Mn) Analysis and Forecast, By Mode of Administration, 2025-2032
- 11.5.1. Topical
- 11.5.2. Oral
- 11.5.3. Injectable
- 11.5.4. Others
- 11.6. Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025-2032
- 11.6.1. Guttate Psoriasis
- 11.6.2. Inverse Psoriasis
- 11.6.3. Pustular Psoriasis
- 11.6.4. Erythrodermic Psoriasis
- 11.6.5. Plaque Psoriasis
- 11.6.6. Others
- 11.7. Market Size (US$ Mn) Analysis and Forecast, By Distribution Channel, 2025-2032
- 11.7.1. Hospital Pharmacies
- 11.7.2. Retail Pharmacies
- 11.7.3. e-Commerce
- 11.8. Market Attractiveness Analysis
- 12. Competition Landscape
- 12.1. Market Share Analysis, 2025
- 12.2. Market Structure
- 12.2.1. Competition Intensity Mapping By Market
- 12.2.2. Competition Dashboard
- 12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
- 12.3.1. Janssen Biotech, Inc.
- 12.3.1.1. Overview
- 12.3.1.2. Segments and Drug Class
- 12.3.1.3. Key Financials
- 12.3.1.4. Market Developments
- 12.3.1.5. Market Strategy
- 12.3.2. Novartis International Ltd.
- 12.3.3. Amgen Inc.
- 12.3.4. Pfizer Inc.
- 12.3.5. Takeda Pharmaceutical Company Ltd.
- 12.3.6. Merck & Co, Inc.
- 12.3.7. AbbVie Inc.
- 12.3.8. Eli Lilly and Company
- 12.3.9. Boehringer Ingelheim GmbH
- 12.3.10. Sun Pharmaceutical Industries Ltd.
- 12.3.11. Johnson & Johnson
- 12.3.12. LEO Pharma
- 12.3.13. UCB
- 12.3.14. AstraZeneca
- 12.3.15. Celgene Corporation
- 12.3.16. Arcutis Biotherapeutics, Inc.
- 12.3.17. Others
- 13. Appendix
- 13.1. Research Methodology
- 13.2. Research Assumptions
- 13.3. Acronyms and Abbreviations
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
